United Therapeutics Stock Cash And Equivalents
| UTH Stock | EUR 277.30 0.60 0.22% |
United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.
United |
United Therapeutics Company Cash And Equivalents Analysis
United Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current United Therapeutics Cash And Equivalents | 1.79 B |
Most of United Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, United Therapeutics has 1.79 B in Cash And Equivalents. This is 118.06% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The cash and equivalents for all Germany stocks is 33.76% higher than that of the company.
Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
United Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.38 % | |||
| Operating Margin | 0.51 % | |||
| Current Valuation | 10.24 B | |||
| Shares Outstanding | 46.3 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Price To Earning | 7.31 X | |||
| Price To Book | 2.73 X | |||
| Price To Sales | 6.30 X | |||
| Revenue | 1.94 B | |||
| Gross Profit | 1.78 B | |||
| EBITDA | 1.03 B | |||
| Net Income | 727.3 M | |||
| Cash And Equivalents | 1.79 B | |||
| Cash Per Share | 40.73 X | |||
| Total Debt | 800 M | |||
| Debt To Equity | 41.30 % | |||
| Current Ratio | 4.62 X | |||
| Book Value Per Share | 104.20 X | |||
| Cash Flow From Operations | 802.5 M | |||
| Earnings Per Share | 13.25 X | |||
| Price To Earnings To Growth | 1.00 X | |||
| Target Price | 231.89 | |||
| Number Of Employees | 965 | |||
| Beta | 0.63 | |||
| Market Capitalization | 10.75 B | |||
| Total Asset | 6.04 B | |||
| Z Score | 7.8 | |||
| Net Asset | 6.04 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in United Stock
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in United Stock please use our How to Invest in United Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.